These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37405389)

  • 1. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies.
    Panza F; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Cirillo N; Damiani C; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Lozupone M
    Expert Opin Investig Drugs; 2023; 32(7):625-634. PubMed ID: 37405389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passive tau-based immunotherapy for tauopathies.
    Panza F; Solfrizzi V; Daniele A; Lozupone M
    Handb Clin Neurol; 2023; 196():611-619. PubMed ID: 37620094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying therapies for tauopathies: agents in the pipeline.
    Panza F; Imbimbo BP; Lozupone M; Greco A; Seripa D; Logroscino G; Daniele A; Colosimo C
    Expert Rev Neurother; 2019 May; 19(5):397-408. PubMed ID: 30973276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
    Lozupone M; Dibello V; Daniele A; Solfrizzi V; Resta E; Panza F
    Expert Opin Pharmacother; 2024 Apr; 25(5):571-584. PubMed ID: 38653731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A walk through tau therapeutic strategies.
    Jadhav S; Avila J; Schöll M; Kovacs GG; Kövari E; Skrabana R; Evans LD; Kontsekova E; Malawska B; de Silva R; Buee L; Zilka N
    Acta Neuropathol Commun; 2019 Feb; 7(1):22. PubMed ID: 30767766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy.
    Karimi N; Bayram Çatak F; Arslan E; Saghazadeh A; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109445. PubMed ID: 36410182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
    Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
    Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
    Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
    J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease: Recent treatment strategies.
    Vaz M; Silvestre S
    Eur J Pharmacol; 2020 Nov; 887():173554. PubMed ID: 32941929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).
    Gibbons GS; Kim SJ; Robinson JL; Changolkar L; Irwin DJ; Shaw LM; Lee VM; Trojanowski JQ
    Acta Neuropathol Commun; 2019 Mar; 7(1):34. PubMed ID: 30832741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focusing on oligomeric tau as a therapeutic target in Alzheimer's disease and other tauopathies.
    Rayman JB
    Expert Opin Ther Targets; 2023; 27(4-5):269-279. PubMed ID: 37140480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease.
    Roberts M; Sevastou I; Imaizumi Y; Mistry K; Talma S; Dey M; Gartlon J; Ochiai H; Zhou Z; Akasofu S; Tokuhara N; Ogo M; Aoyama M; Aoyagi H; Strand K; Sajedi E; Agarwala KL; Spidel J; Albone E; Horie K; Staddon JM; de Silva R
    Acta Neuropathol Commun; 2020 Feb; 8(1):13. PubMed ID: 32019610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
    Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of tau binding by gosuranemab.
    Sopko R; Golonzhka O; Arndt J; Quan C; Czerkowicz J; Cameron A; Smith B; Murugesan Y; Gibbons G; Kim SJ; Trojanowski JQ; Lee VMY; Brunden KR; Graham DL; Weinreb PH; Hering H
    Neurobiol Dis; 2020 Dec; 146():105120. PubMed ID: 32991997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tau: Clinical trials and novel therapeutic approaches.
    VandeVrede L; Boxer AL; Polydoro M
    Neurosci Lett; 2020 Jul; 731():134919. PubMed ID: 32380145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective tau tyrosine nitration in non-AD tauopathies.
    Reyes JF; Geula C; Vana L; Binder LI
    Acta Neuropathol; 2012 Jan; 123(1):119-32. PubMed ID: 22057784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Overview on the Clinical Development of Tau-Based Therapeutics.
    Medina M
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
    Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
    Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for progressive supranuclear palsy.
    Giagkou N; Stamelou M
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):83-92. PubMed ID: 31007097
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.